Literature DB >> 25824688

How I treat and manage strokes in sickle cell disease.

Adetola A Kassim1, Najibah A Galadanci2, Sumit Pruthi3, Michael R DeBaun4.   

Abstract

Neurologic complications are a major cause of morbidity and mortality in sickle cell disease (SCD). In children with sickle cell anemia, routine use of transcranial Doppler screening, coupled with regular blood transfusion therapy, has decreased the prevalence of overt stroke from ∼11% to 1%. Limited evidence is available to guide acute and chronic management of individuals with SCD and strokes. Current management strategies are based primarily on single arm clinical trials and observational studies, coupled with principles of neurology and hematology. Initial management of a focal neurologic deficit includes evaluation by a multidisciplinary team (a hematologist, neurologist, neuroradiologist, and transfusion medicine specialist); prompt neuro-imaging and an initial blood transfusion (simple followed immediately by an exchange transfusion or only exchange transfusion) is recommended if the hemoglobin is >4 gm/dL and <10 gm/dL. Standard therapy for secondary prevention of strokes and silent cerebral infarcts includes regular blood transfusion therapy and in selected cases, hematopoietic stem cell transplantation. A critical component of the medical care following an infarct is cognitive and physical rehabilitation. We will discuss our strategy of acute and long-term management of strokes in SCD.
© 2015 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2015        PMID: 25824688      PMCID: PMC4467906          DOI: 10.1182/blood-2014-09-551564

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  89 in total

1.  Neurologic events after partial exchange transfusion for priapism in sickle cell disease.

Authors:  W R Rackoff; K Ohene-Frempong; S Month; J P Scott; B Neahring; A R Cohen
Journal:  J Pediatr       Date:  1992-06       Impact factor: 4.406

2.  Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia.

Authors:  Michael R DeBaun; Mae Gordon; Robert C McKinstry; Michael J Noetzel; Desiree A White; Sharada A Sarnaik; Emily R Meier; Thomas H Howard; Suvankar Majumdar; Baba P D Inusa; Paul T Telfer; Melanie Kirby-Allen; Timothy L McCavit; Annie Kamdem; Gladstone Airewele; Gerald M Woods; Brian Berman; Julie A Panepinto; Beng R Fuh; Janet L Kwiatkowski; Allison A King; Jason M Fixler; Melissa M Rhodes; Alexis A Thompson; Mark E Heiny; Rupa C Redding-Lallinger; Fenella J Kirkham; Natalia Dixon; Corina E Gonzalez; Karen A Kalinyak; Charles T Quinn; John J Strouse; J Philip Miller; Harold Lehmann; Michael A Kraut; William S Ball; Deborah Hirtz; James F Casella
Journal:  N Engl J Med       Date:  2014-08-21       Impact factor: 91.245

3.  Long-term results using hydroxyurea/phlebotomy for reducing secondary stroke risk in children with sickle cell anemia and iron overload.

Authors:  Anthea Greenway; Russell E Ware; Courtney D Thornburg
Journal:  Am J Hematol       Date:  2011-04       Impact factor: 10.047

4.  Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.

Authors:  Lewis B Morgenstern; J Claude Hemphill; Craig Anderson; Kyra Becker; Joseph P Broderick; E Sander Connolly; Steven M Greenberg; James N Huang; R Loch MacDonald; Steven R Messé; Pamela H Mitchell; Magdy Selim; Rafael J Tamargo
Journal:  Stroke       Date:  2010-07-22       Impact factor: 7.914

5.  Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke.

Authors:  Douglas J Scothorn; Cynthia Price; Daniel Schwartz; Cindy Terrill; George R Buchanan; Wanda Shurney; Ingrid Sarniak; Robert Fallon; Jen-Yih Chu; Charles H Pegelow; Winfred Wang; James F Casella; Linda S Resar; Brian Berman; Thomas Adamkiewicz; Lewis L Hsu; Kwaku Ohene-Frempong; Kim Smith-Whitley; Donald Mahoney; J Paul Scott; Gerald M Woods; Masayo Watanabe; Michael R Debaun
Journal:  J Pediatr       Date:  2002-03       Impact factor: 4.406

6.  Exchange blood transfusion compared with simple transfusion for first overt stroke is associated with a lower risk of subsequent stroke: a retrospective cohort study of 137 children with sickle cell anemia.

Authors:  Monica L Hulbert; Douglas J Scothorn; Julie A Panepinto; J Paul Scott; George R Buchanan; Sharada Sarnaik; Robert Fallon; Jen-Yih Chu; Winfred Wang; James F Casella; Linda Resar; Brian Berman; Thomas Adamkiewicz; Lewis L Hsu; Kimberly Smith-Whitley; Donald Mahoney; Gerald Woods; Masayo Watanabe; Michael R DeBaun
Journal:  J Pediatr       Date:  2006-11       Impact factor: 4.406

7.  Pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine infusions.

Authors:  M H Freedman; D Grisaru; N Olivieri; I MacLusky; P S Thorner
Journal:  Am J Dis Child       Date:  1990-05

8.  Transient disappearance of cerebral infarcts on CT scan, the so-called fogging effect.

Authors:  E B Skriver; T S Olsen
Journal:  Neuroradiology       Date:  1981       Impact factor: 2.804

9.  Cardiac iron overload in sickle-cell disease.

Authors:  Antonella Meloni; Mammen Puliyel; Alessia Pepe; Vasili Berdoukas; Thomas D Coates; John C Wood
Journal:  Am J Hematol       Date:  2014-04-15       Impact factor: 10.047

10.  Hypertension and convulsions complicating sickle cell anaemia: possible role of transfusion.

Authors:  J M Hamdan; A A Mallouh; M S Ahmad
Journal:  Ann Trop Paediatr       Date:  1984-03
View more
  34 in total

1.  Reduction in Overt and Silent Stroke Recurrence Rate Following Cerebral Revascularization Surgery in Children with Sickle Cell Disease and Severe Cerebral Vasculopathy.

Authors:  Erin M Hall; Jeffrey Leonard; Jodi L Smith; Kristin P Guilliams; Michael Binkley; Robert J Fallon; Monica L Hulbert
Journal:  Pediatr Blood Cancer       Date:  2016-04-22       Impact factor: 3.167

Review 2.  Metabolomic and molecular insights into sickle cell disease and innovative therapies.

Authors:  Morayo G Adebiyi; Jeanne M Manalo; Yang Xia
Journal:  Blood Adv       Date:  2019-04-23

3.  PRIMARY STROKE PREVENTION IN CHILDREN WITH SICKLE CELL ANEMIA LIVING IN AFRICA: THE FALSE CHOICE BETWEEN PATIENT-ORIENTED RESEARCH AND HUMANITARIAN SERVICE.

Authors:  Michael R Debaun; Najibah A Galadanci; Adetola A Kassim; Lori C Jordan; Sharon Phillips; Muktar H Aliyu
Journal:  Trans Am Clin Climatol Assoc       Date:  2016

4.  Effects of red blood cell (RBC) transfusion on sickle cell disease recipient plasma and RBC metabolism.

Authors:  Rachel Culp-Hill; Amudan J Srinivasan; Sarah Gehrke; Reed Kamyszek; Andrea Ansari; Nirmish Shah; Ian Welsby; Angelo D'Alessandro
Journal:  Transfusion       Date:  2018-09-28       Impact factor: 3.157

Review 5.  Sickle cell disease: a malady beyond a hemoglobin defect in cerebrovascular disease.

Authors:  Junaid Ansari; Youmna E Moufarrej; Rafal Pawlinski; Felicity N E Gavins
Journal:  Expert Rev Hematol       Date:  2017-12-05       Impact factor: 2.929

Review 6.  Chronic organ failure in adult sickle cell disease.

Authors:  Elliott Vichinsky
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

7.  Children with sickle cell anemia with normal transcranial Doppler ultrasounds and without silent infarcts have a low incidence of new strokes.

Authors:  Lori C Jordan; Dionna O Roberts Williams; Mark J Rodeghier; Brittany V Covert Greene; Maria R Ponisio; James F Casella; Robert C McKinstry; Michael J Noetzel; Fenella J Kirkham; Emily R Meier; Beng Fuh; Melissa McNaull; Sharada Sarnaik; Suvankar Majumdar; Timothy L McCavit; Michael R DeBaun
Journal:  Am J Hematol       Date:  2018-03-30       Impact factor: 10.047

Review 8.  Novel insights in the management of sickle cell disease in childhood.

Authors:  Lorenzo Iughetti; Elena Bigi; Donatella Venturelli
Journal:  World J Clin Pediatr       Date:  2016-02-08

Review 9.  Neurologic Complications of Sickle Cell Disease.

Authors:  Shama Farooq; Fernando D Testai
Journal:  Curr Neurol Neurosci Rep       Date:  2019-02-28       Impact factor: 5.081

10.  Hydroxyurea use in Children with Sickle Cell Disease: Do Severely Affected Patients Use It and Does It Impact Hospitalization Outcomes?

Authors:  Susan E Creary; Deena J Chisolm; Terah L Koch; Victoria A Zigmont; Bo Lu; Sarah H O'Brien
Journal:  Pediatr Blood Cancer       Date:  2016-01-21       Impact factor: 3.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.